JP6865211B2 - 改変された炭疽毒素保護抗原 - Google Patents

改変された炭疽毒素保護抗原 Download PDF

Info

Publication number
JP6865211B2
JP6865211B2 JP2018510419A JP2018510419A JP6865211B2 JP 6865211 B2 JP6865211 B2 JP 6865211B2 JP 2018510419 A JP2018510419 A JP 2018510419A JP 2018510419 A JP2018510419 A JP 2018510419A JP 6865211 B2 JP6865211 B2 JP 6865211B2
Authority
JP
Japan
Prior art keywords
amino acid
cells
tumor
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018510419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527926A (ja
JP2018527926A5 (enExample
Inventor
リュー、シ−フィ
エイチ． レップラ、ステファン
エイチ． レップラ、ステファン
エイチ． ブッゲ、トーマス
エイチ． ブッゲ、トーマス
エヌ． ウェイン、アレキサンダー
エヌ． ウェイン、アレキサンダー
イー． ピーターズ、ダイアン
イー． ピーターズ、ダイアン
リュー、ジエ
チェン、クアン−ホア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2018527926A publication Critical patent/JP2018527926A/ja
Publication of JP2018527926A5 publication Critical patent/JP2018527926A5/ja
Application granted granted Critical
Publication of JP6865211B2 publication Critical patent/JP6865211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018510419A 2015-08-27 2016-08-25 改変された炭疽毒素保護抗原 Active JP6865211B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562210771P 2015-08-27 2015-08-27
US62/210,771 2015-08-27
US201662323218P 2016-04-15 2016-04-15
US62/323,218 2016-04-15
PCT/US2016/048706 WO2017035359A1 (en) 2015-08-27 2016-08-25 Modified anthrax toxin protective antigen

Publications (3)

Publication Number Publication Date
JP2018527926A JP2018527926A (ja) 2018-09-27
JP2018527926A5 JP2018527926A5 (enExample) 2019-10-03
JP6865211B2 true JP6865211B2 (ja) 2021-04-28

Family

ID=56943920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510419A Active JP6865211B2 (ja) 2015-08-27 2016-08-25 改変された炭疽毒素保護抗原

Country Status (7)

Country Link
US (1) US10835593B2 (enExample)
EP (1) EP3341393B1 (enExample)
JP (1) JP6865211B2 (enExample)
KR (1) KR20180073555A (enExample)
CN (1) CN108350041A (enExample)
AU (1) AU2016311429C1 (enExample)
WO (1) WO2017035359A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073555A (ko) 2015-08-27 2018-07-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 변형된 탄저균 독소 방어 항원
CA3119599A1 (en) 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Als treatment using induced regulatory t (itreg) cells
EP4150060A4 (en) * 2020-05-13 2024-06-19 Rapa Therapeutics, LLC TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT)
JP7648075B2 (ja) * 2020-11-27 2025-03-18 株式会社ダイセル 融合タンパク質
CN117343942B (zh) * 2023-12-06 2024-02-13 南京市食品药品监督检验院 一种pagA重组蛋白及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214340B1 (en) 1999-09-24 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2005090393A2 (en) * 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
US20100168012A1 (en) 2006-12-14 2010-07-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture
CN101215568B (zh) 2008-01-18 2010-06-23 畿晋庆三联（北京）生物技术有限公司 抗炭疽多肽及其应用与制备方法
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
SG11201602012RA (en) 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
KR20180073555A (ko) 2015-08-27 2018-07-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 변형된 탄저균 독소 방어 항원

Also Published As

Publication number Publication date
JP2018527926A (ja) 2018-09-27
EP3341393A1 (en) 2018-07-04
US10835593B2 (en) 2020-11-17
KR20180073555A (ko) 2018-07-02
AU2016311429A1 (en) 2018-04-19
WO2017035359A1 (en) 2017-03-02
AU2016311429C1 (en) 2021-10-07
US20180250376A1 (en) 2018-09-06
CN108350041A (zh) 2018-07-31
AU2016311429B2 (en) 2021-07-08
CA2996767A1 (en) 2017-03-02
EP3341393B1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
JP5904985B2 (ja) 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
JP7724601B2 (ja) 腫瘍溶解性ウイルス療法
CN105008397B (zh) 作为治疗试剂的Gla结构域
CN1309734C (zh) 与免疫应答有关的新颖多肽
EP3341393B1 (en) Modified anthrax toxin protective antigen
JP2007506789A (ja) Ｉｌ−２１を用いた自己免疫疾患の治療方法
CN111050784B (zh) 截短的豚鼠l-天冬酰胺酶变体及其使用方法
CN102341407A (zh) 作为补体抑制剂的经修饰的omci
AU2020307688B2 (en) Combination cancer immunotherapy
JP2023506681A (ja) 免疫調節のための化合物
US20260021139A1 (en) Combination of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of use
CA2996767C (en) Modified anthrax toxin protective antigen
JP4273234B2 (ja) チオレドキシン改変体
EP4687956A1 (en) Methods for enhancing the immunogenicity of cellular vaccines
CN121406676A (zh) 用于免疫细胞衔接剂的核酸和药物组合物
WO2018230628A1 (ja) ファブリー病治療用医薬の組合せ物及びその利用

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210405

R150 Certificate of patent or registration of utility model

Ref document number: 6865211

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250